![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/06/2925466/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Second-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/07/30/2921370/0/en/Aligos-Therapeutics-to-Announce-2nd-Quarter-2024-Financial-Results-on-August-6-2024.html
https://www.globenewswire.com/news-release/2024/07/22/2916551/0/en/Aligos-Therapeutics-Announces-Clinical-Collaboration-with-Xiamen-Amoytop-Biotech-Co-Ltd.html
https://www.globenewswire.com/news-release/2024/07/10/2911059/0/en/Aligos-Therapeutics-to-Host-KOL-Event-to-Discuss-the-Positive-Phase-1b-Data-from-ALG-000184-for-the-Treatment-of-CHB.html
https://www.globenewswire.com/news-release/2024/06/05/2893577/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-the-EASL-Congress-2024.html
https://www.globenewswire.com/news-release/2024/05/22/2886841/0/en/Aligos-Therapeutics-Announces-Six-Abstracts-Accepted-for-Presentation-at-EASL-2024.html
https://www.globenewswire.com/news-release/2024/05/21/2885520/0/en/Aligos-Therapeutics-Announces-the-Completion-of-Enrollment-in-the-ALG-055009-Phase-2a-HERALD-Study-for-the-Treatment-of-MASH.html
https://www.globenewswire.com/news-release/2024/05/07/2877224/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com/news-release/2024/04/30/2872761/0/en/Aligos-Therapeutics-to-Announce-1st-Quarter-2024-Financial-Results-on-May-7-2024.html
https://www.globenewswire.com/news-release/2024/04/25/2870049/0/en/Aligos-Therapeutics-Presents-Positive-Clinical-Data-at-ESCMID-2024-from-the-ALG-097558-Phase-1-Study.html